ArticleBritish journal of cancer2014
Inflammation as a validated prognostic determinant in carcinoma of unknown primary site.
Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Prognostic value of PLR in various cancers: a meta-analysis.PloS one · 2014Pooled it
- Article
- Prediction of Survival Prognosis for Spinal Metastasis From Cancer of Unknown Primary: Derivation and Validation of a Nomogram Model.Global spine journal · 2024Article
- Neutrophil/lymphocyte ratio predicts lymph node metastasis in patients with gastric cancer.American journal of translational research · 2023Article
- A generational comparison for unfavorable cancer of unknown primary in a single institute over 20 years.Cancer medicine · 2023Article
- Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Extensive diagnostic work-up for patients with carcinoma of unknown primary.Clinical & experimental metastasis · 2021Article
- Prognostic significance of systemic inflammatory markers in esophageal cancer: Systematic review and meta-analysis.Annals of gastroenterological surgery · 2020Review
- Review
- Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology.Virchows Archiv : an international journal of pathology · 2019Review
- 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Review
- The hematologic markers as prognostic factors in patients with resectable gastric cancer.Cancer biomarkers : section A of Disease markers · 2016Article
- Article
- A Simple Risk Model to Predict Survival in Patients With Carcinoma of Unknown Primary Origin.Medicine · 2015Article
- Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer.British journal of cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundCarcinoma of unknown primary (CUP) is a clinical presentation with a poor prognosis. Inflammation-based prognostic systems are stage-independent prognostic predictors in various malignancies. We aimed to assess the accuracy of the modified Glasgow Prognostic Score (mGPS), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) as objective prognostic models in CUP.
methodsWe derived inflammatory scores in 60 consecutive CUP referrals to the Imperial College oncology unit between 1996 and 2011. Patient demographics, treatment and staging data and full blood profiles were collected. An independent cohort of 179 patients presenting to the Taipei Veterens Hospital between 2000 and 2009 were used as a 'validation' data set. Uni- and multivariate survival analysis was used to predict the overall survival (OS).
resultsSixty patients were included: median age 61 (range: 33-86); 51% men; median OS 5.9 months (0.7-42.9); 88% with distant metastases. On univariate analysis NLR >5 (P=0.04) and mGPS (score 1-2) (P=0.03) correlated with OS. Multivariate analysis demonstrated significant hazard ratios for NLR; 2.02 (CI 1.0-4.1) (P=0.04) and mGPS; 1.52 (CI 1.0-2.3) (P=0.03). These findings were reinforced by analysis of the validation data.
conclusionNLR and mGPS are independent, externally validated prognostic markers in CUP, with superior objectivity compared with performance status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.